Literature DB >> 15254433

Mdmx and Mdm2: brothers in arms?

Jean-Christophe Marine1, Aart G Jochemsen.   

Abstract

The p53 tumor suppressor pathway is inactivated in most if not all human tumors. In about 50% of the cases this is accomplished directly by gene mutations. The tumors that retain wild type p53 frequently show defects either in effector target genes, or in the expression of p53 regulatory proteins. The Mdm2 protein is generally considered THE master regulator of the p53 tumor suppressor activity. Recently, however, the Mdm2-related protein Mdmx is taking the stage in the p53-Mdm2-Mdmx play. We summarize here observations unambiguously assigning a critical role for the Mdmx protein in the regulation of p53 function during development and tumor formation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15254433

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  36 in total

1.  Spontaneous tumorigenesis in mice overexpressing the p53-negative regulator Mdm4.

Authors:  Shunbin Xiong; Vinod Pant; Young-Ah Suh; Carolyn S Van Pelt; Yongxing Wang; Yasmine A Valentin-Vega; Sean M Post; Guillermina Lozano
Journal:  Cancer Res       Date:  2010-08-24       Impact factor: 12.701

2.  Turning the RING domain protein MdmX into an active ubiquitin-protein ligase.

Authors:  Saravanakumar Iyappan; Hans-Peter Wollscheid; Alejandro Rojas-Fernandez; Andreas Marquardt; Hao-Cheng Tang; Rajesh K Singh; Martin Scheffner
Journal:  J Biol Chem       Date:  2010-08-12       Impact factor: 5.157

3.  Interplay between MDM2, MDMX, Pirh2 and COP1: the negative regulators of p53.

Authors:  Lan Wang; Guifen He; Pingzhao Zhang; Xiang Wang; Mei Jiang; Long Yu
Journal:  Mol Biol Rep       Date:  2010-03-24       Impact factor: 2.316

4.  Structural and functional comparison of the RING domains of two p53 E3 ligases, Mdm2 and Pirh2.

Authors:  Jonathan Shloush; John E Vlassov; Ian Engson; Shili Duan; Vivian Saridakis; Sirano Dhe-Paganon; Brian Raught; Yi Sheng; Cheryl H Arrowsmith
Journal:  J Biol Chem       Date:  2010-11-17       Impact factor: 5.157

5.  Differential roles of ATM- and Chk2-mediated phosphorylations of Hdmx in response to DNA damage.

Authors:  Yaron Pereg; Suzanne Lam; Amina Teunisse; Sharon Biton; Erik Meulmeester; Leonid Mittelman; Giacomo Buscemi; Koji Okamoto; Yoichi Taya; Yosef Shiloh; Aart G Jochemsen
Journal:  Mol Cell Biol       Date:  2006-09       Impact factor: 4.272

6.  MDMX promotes proteasomal turnover of p21 at G1 and early S phases independently of, but in cooperation with, MDM2.

Authors:  Yetao Jin; Shelya X Zeng; Xiao-Xin Sun; Hunjoo Lee; Christine Blattner; Zhixiong Xiao; Hua Lu
Journal:  Mol Cell Biol       Date:  2007-12-17       Impact factor: 4.272

7.  p53-Responsive micrornas 192 and 215 are capable of inducing cell cycle arrest.

Authors:  Christian J Braun; Xin Zhang; Irina Savelyeva; Sonja Wolff; Ute M Moll; Troels Schepeler; Torben F Ørntoft; Claus L Andersen; Matthias Dobbelstein
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

Review 8.  The genomic landscape of retinoblastoma: a review.

Authors:  Brigitte L Thériault; Helen Dimaras; Brenda L Gallie; Timothy W Corson
Journal:  Clin Exp Ophthalmol       Date:  2013-05-22       Impact factor: 4.207

9.  MDMX is a prognostic factor for non-small cell lung cancer and regulates its sensitivity to cisplatin.

Authors:  Han Zhao; Yu-Zhuo Xie; Rui Xing; Ming Sun; Feng Chi; Yue-Can Zeng
Journal:  Cell Oncol (Dordr)       Date:  2017-05-31       Impact factor: 6.730

10.  Identification and characterization of the first small molecule inhibitor of MDMX.

Authors:  Damon Reed; Ying Shen; Anang A Shelat; Leggy A Arnold; Antonio M Ferreira; Fangyi Zhu; Nicholas Mills; David C Smithson; Catherine A Regni; Donald Bashford; Samantha A Cicero; Brenda A Schulman; Aart G Jochemsen; R Kiplin Guy; Michael A Dyer
Journal:  J Biol Chem       Date:  2010-01-15       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.